Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
2seventy bio
Pharma
FDA calls for adcomm on BMS's Abecma in earlier treatment line
BMS's effort to gain approval for Abecma in an earlier line of treatment—set for an FDA decision on Dec. 16—will be pushed back pending an FDA adcomm.
Kevin Dunleavy
Nov 20, 2023 11:30am
2seventy suffers CAR-T commercialization pitfalls with Abecma
Nov 15, 2023 11:10am
Sumitomo-Myovant, Astellas-Taysha, Genentech—Fierce Pharma Asia
Oct 28, 2022 9:15am
